Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 68% of Prescriptions Permit Generic Substitution, But 88% of Them Not Filled with Generics: Survey
November 30, 2009
- Sato Pharm. Launches Switch OTC Version of Vidarabine
November 30, 2009
- Otsuka HD: Pharma Division Sales Total ¥357.5 Bil.
November 30, 2009
- Market for Generics to Expand to ¥447.9 Bil. in 2011: Fuji Keizai
November 30, 2009
- Kobayashi Pharm.: Sales Up 4.9% due to Influenza Pandemic
November 30, 2009
- Kaken Licenses bFGF to Olympus in Europe, North America
November 30, 2009
- Generics Dispensing Rate Has No Clear Effects on Pharmacies' Business
November 30, 2009
- Adverse Reactions Reported due to GSK's Flu Vaccine
November 30, 2009
- Zeria Aims at 50% Market Share for Asacol: President Ibe
November 30, 2009
- NDA for Liraglutide, Vildagliptin to Be Reviewed
November 30, 2009
- JDS to Include HbA1c in Its Diagnostic Criteria
November 30, 2009
- Sciele Pharma to Acquire Addrenex: Shionogi
November 30, 2009
- JPMA President Stresses the Need for Price Maintenance System
November 30, 2009
- Rohto Posts Record-High Sales Driven by Cosmetic Business
November 30, 2009
- Blopress Japan's Best-Selling Drug in 2nd Qtr: IMS Japan
November 30, 2009
- FJPWA President Expresses Great Concern about GRU WG's Recommendation
November 30, 2009
- JSA Revises Its GL on Prevention and Management of Asthma
November 30, 2009
- Growth of CRO Business Slows Down due to Megamergers: Mr Nakamura
November 30, 2009
- Non-clinical Evaluation of Anticancer Drugs Reaches Step 4 at ICH
November 30, 2009
- Business Improves for Hospitals and Worsens for GPs, Pharmacies
November 30, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…